PMID- 33363463
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240330
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 11
DP  - 2020
TI  - The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer.
PG  - 574667
LID - 10.3389/fphar.2020.574667 [doi]
LID - 574667
AB  - Chemokines are a family of small, secreted cytokines which regulate a variety of 
      cell functions. The C-X-C motif chemokine ligand 12 (CXCL12) binds to C-X-C 
      chemokine receptor type 4 (CXCR4) and C-X-C chemokine receptor type 7 (CXCR7). 
      The interaction of CXCL12 and its receptors subsequently induces downstream 
      signaling pathways with broad effects on chemotaxis, cell proliferation, 
      migration, and gene expression. Accumulating evidence suggests that the 
      CXCL12/CXCR4/CXCR7 axis plays a pivotal role in tumor development, survival, 
      angiogenesis, metastasis, and tumor microenvironment. In addition, this chemokine 
      axis promotes chemoresistance in cancer therapy via complex crosstalk with other 
      pathways. Multiple small molecules targeting CXCR4/CXCR7 have been developed and 
      used for preclinical and clinical cancer treatment. In this review, we describe 
      the roles of the CXCL12/CXCR4/CXCR7 axis in cancer progression and summarize 
      strategies to develop novel targeted cancer therapies.
CI  - Copyright (c) 2020 Shi, Riese and Shen.
FAU - Shi, Yi
AU  - Shi Y
AD  - Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn 
      University, Auburn, AL, United States.
FAU - Riese, David J 2nd
AU  - Riese DJ 2nd
AD  - Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn 
      University, Auburn, AL, United States.
FAU - Shen, Jianzhong
AU  - Shen J
AD  - Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn 
      University, Auburn, AL, United States.
LA  - eng
GR  - R01 CA114209/CA/NCI NIH HHS/United States
GR  - R01 HL125279/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20201208
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC7753359
OTO - NOTNLM
OT  - C-X-C chemokine receptor type 4
OT  - C-X-C chemokine receptor type 7
OT  - C-X-C motif chemokine ligand 12
OT  - cancer progression
OT  - tumor microenvironment
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
PMCR- 2020/12/08
CRDT- 2020/12/28 11:59
PHST- 2020/06/20 00:00 [received]
PHST- 2020/10/29 00:00 [accepted]
PHST- 2020/12/28 11:59 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
PHST- 2020/12/08 00:00 [pmc-release]
AID - 574667 [pii]
AID - 10.3389/fphar.2020.574667 [doi]
PST - epublish
SO  - Front Pharmacol. 2020 Dec 8;11:574667. doi: 10.3389/fphar.2020.574667. 
      eCollection 2020.